Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivasorexant Phase 1 SAD/MAD in Healthy Subjects
NCT02702648Phase 1Completed
- Sponsor
- Idorsia
- Start
- Feb 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nivasorexant in binge eating disorder (BED) and anxiety disorders (4 arms), sponsored by Idorsia. Primary endpoints: Number of participants with adverse events (AEs), Changes from baseline in vital signs and 1 more. Started Feb 2016; status: completed.
02
Drugs
nivasorexant
03
Conditions
binge eating disorder (BED)anxiety disorders
Beyond the preview
Go deeper on NCT02702648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702648.